Bluejay Diagnostics (BJDX) Short term Debt (2020 - 2021)
Bluejay Diagnostics (BJDX) posted Short term Debt of $2000.0 for Q4 2021, down 98.26% sequentially from $115102.0 in Q3 2021, and down 98.4% YoY from $125102.0 in Q4 2020.
Bluejay Diagnostics (BJDX) Short term Debt (2020 - 2021) Analysis & Trends
Bluejay Diagnostics has reported Short term Debt for 2 years, with the latest figure at $2000.0 in Q4 2021.
- Quarterly Short term Debt fell 98.4% year-over-year to $2000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $2000.0 (down 98.4% YoY) and the FY2021 annual result came in at $2000.0, down 98.4% from the prior year.
- Short term Debt fell to $2000.0 in Q4 2021 per BJDX's latest filing, from $115102.0 in the prior quarter.
- Over five years, Short term Debt peaked at $125102.0 in Q4 2020 and troughed at $2000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Bluejay Diagnostics | 1.89 Mn | 1.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 115,102.00 |
| Dec 31, 2020 | 125,102.00 |